Datroway (Datopotamab Deruxtecan) Projected peak annual sales: USD 5 billion Datopotamab deruxtecan, jointly developed by Daiichi Sankyo and AstraZeneca, is a specifically engineered TROP2-directed DXd ADC used for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and EGFR-mutated non-small cell lung cancer (NSCLC)
Since oxidative stress is associated with muscle fatigue, the use of NAC has also been explored in athletes
Discussion This review covers the importance of maintaining NAD + levels for cellular homeostasis and mitochondrial maintenance, as well as evaluating established and novel NAD + boosting strategies from simple supplementation of precursors to modulation of enzymes by drugs
This blend allows researchers to track steady-state data across multiple regulatory mechanisms simultaneously without requiring multi-vial cross-contamination risks
An 11-Year retrospective analysis of candidiasis epidemiology, risk factors, and antifungal susceptibility in a tertiary care hospital in China
